Accession Number:



Developing Novel Therapeutics Targeting Undifferentiated and Castration-Resistant Prostate Cancer Stem Cells

Descriptive Note:

Technical Report,29 Sep 2015,28 Sep 2016

Corporate Author:

University of Texas MD Anderson Cancer Center Houston United States

Personal Author(s):

Report Date:


Pagination or Media Count:



The main objective of this DOD-supported project is to identify and develop novel therapeutics to target the undifferentiated PSA-lo, castration-resistant PCSCs. We proposed to achieve this objective with two Specific Aims 1 To perform phage display library PDL screening in PSA-lo PCa cells to identify PCSC-specific homing peptides and 2 To perform unbiased drug library screening to identify novel PCSC-targeting chemicals. In the past year, we have accomplished all goals in Aim 2 with a comprehensive publication in Oncotarget. We have also made some progress for Specific Aim 1. Dr. Tang, the PI of this grant, together with most lab members, moved from the M.D Anderson Cancer Center MDACC to Roswell Park Cancer Institute RPCI on June 1 of 2016. During the period of May 1 early July of 2016, the lab had been mostly focused on moving related matters and therefore there was a gap in executing experiments related to this project. In the last year of the grant period, we request the transfer of the remaining balance for this grant to the RPCI in order to complete all goals proposed in Aim 1.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology
  • Biochemistry

Distribution Statement: